ArticleBlood2015
The predictive strength of next-generation sequencing MRD detection for relapse compared with current methods in childhood ALL.
Abstract readLetter
In one paragraph
Article in Blood, 2015. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 48 papers.
0numbers the graph read from it
0cells of the map it votes in
48citing papers in PubMed
–field-weighted citation impact
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
48 citing papers in PubMed.
- Ultrasensitive detection of acute myeloid leukemia minimal residual disease using single molecule molecular inversion probes.Haematologica · 2017Trial
- Next-generation sequencing indicates false-positive MRD results and better predicts prognosis after SCT in patients with childhood ALL.Bone marrow transplantation · 2017Trial
- Measurable residual disease detected by next-generation sequencing in T-cell acute lymphoblastic leukemia.Nature communications · 2026Article
- Mutational analysis of primary and advanced chordoma tissue using next-generation sequencing.Cancer · 2025Article
- Minimal Residual Disease Detection: Implications for Clinical Diagnosis and Cancer Patient Treatment.MedComm · 2025Review
- Article
- [Current situation and prospect of minimal residual disease in pediatric T cell acute lymphoblastic leukemia].Zhonghua xue ye xue za zhi = Zhonghua xueyexue zazhi · 2025Review
- [Next-generation sequencing-based minimal residual disease detection reveals clonal evolution in pediatric acute B-lymphoblastic leukemia: a case report and literature review].Zhonghua xue ye xue za zhi = Zhonghua xueyexue zazhi · 2024Review
- The gray area of RQ-PCR-based measurable residual disease: subdividing the "positive, below quantitative range" category.Leukemia · 2024Article
- Monitoring measurable residual disease in paediatric acute lymphoblastic leukaemia using immunoglobulin gene clonality based on next-generation sequencing.Cancer cell international · 2024Article
- The effectiveness of blinatumomab in clearing measurable residual disease in pediatric B-cell acute lymphoblastic leukemia patients detected by next-generation sequencing.Cancer medicine · 2023Article
- Clinical application of next-generation sequencing-based monitoring of minimal residual disease in childhood acute lymphoblastic leukemia.Journal of cancer research and clinical oncology · 2023Article
- Minimal residual disease detection by mutation-specific droplet digital PCR for leukemia/lymphoma.International journal of hematology · 2023Article
- Article
- Optimizing Molecular Minimal Residual Disease Analysis in Adult Acute Lymphoblastic Leukemia.Cancers · 2023Review
- High-sensitivity next-generation sequencing MRD assessment in ALL identifies patients at very low risk of relapse.Blood advances · 2022Article
- Prognostic value of low-level MRD in adult acute lymphoblastic leukemia detected by low- and high-throughput methods.Blood advances · 2022Article
- Review
- Immunoglobulin Heavy Chain High-Throughput Sequencing in Pediatric B-Precursor Acute Lymphoblastic Leukemia: Is the Clonality of the Disease at Diagnosis Related to Its Prognosis?Frontiers in pediatrics · 2022Article
- Circulating Tumor DNA in Pediatric Cancer.Frontiers in molecular biosciences · 2022Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
15 authors.
Michaela KotrovaChildhood Leukaemia Investigation Prague (CLIP), Department of Pediatric Hematology/Oncology, 2nd Faculty of Medicine, Charles University and University Hospital Motol, Prague, Czech Republic.
Katerina MuzikovaChildhood Leukaemia Investigation Prague (CLIP), Department of Pediatric Hematology/Oncology, 2nd Faculty of Medicine, Charles University and University Hospital Motol, Prague, Czech Republic.
Ester MejstrikovaChildhood Leukaemia Investigation Prague (CLIP), Department of Pediatric Hematology/Oncology, 2nd Faculty of Medicine, Charles University and University Hospital Motol, Prague, Czech Republic.
Michaela NovakovaChildhood Leukaemia Investigation Prague (CLIP), Department of Pediatric Hematology/Oncology, 2nd Faculty of Medicine, Charles University and University Hospital Motol, Prague, Czech Republic.
Violeta Bakardjieva-MihaylovaChildhood Leukaemia Investigation Prague (CLIP), Department of Pediatric Hematology/Oncology, 2nd Faculty of Medicine, Charles University and University Hospital Motol, Prague, Czech Republic.
Karel FiserChildhood Leukaemia Investigation Prague (CLIP), Department of Pediatric Hematology/Oncology, 2nd Faculty of Medicine, Charles University and University Hospital Motol, Prague, Czech Republic.
Jan StuchlyChildhood Leukaemia Investigation Prague (CLIP), Department of Pediatric Hematology/Oncology, 2nd Faculty of Medicine, Charles University and University Hospital Motol, Prague, Czech Republic.
Mathieu GiraudCRIStAL (Centre de Recherche en Informatique, Signal et Automatique de Lille), Unité Mixte de Recherche (UMR CNRS 9189), Université de Lille and Inria Lille, Lille, France.
Mikaël SalsonCRIStAL (Centre de Recherche en Informatique, Signal et Automatique de Lille), Unité Mixte de Recherche (UMR CNRS 9189), Université de Lille and Inria Lille, Lille, France.
Christiane PottSecond Medical Department, University Hospital Schleswig-Holstein, Campus Kiel, Kiel, Germany.
Monika BrüggemannSecond Medical Department, University Hospital Schleswig-Holstein, Campus Kiel, Kiel, Germany.
Marc FüllgrabeSecond Medical Department, University Hospital Schleswig-Holstein, Campus Kiel, Kiel, Germany.
Jan StaryDepartment of Pediatric Hematology/Oncology, 2nd Faculty of Medicine, Charles University and University Hospital Motol, Prague, Czech Republic.
Jan TrkaChildhood Leukaemia Investigation Prague (CLIP), Department of Pediatric Hematology/Oncology, 2nd Faculty of Medicine, Charles University and University Hospital Motol, Prague, Czech Republic.
Eva FronkovaChildhood Leukaemia Investigation Prague (CLIP), Department of Pediatric Hematology/Oncology, 2nd Faculty of Medicine, Charles University and University Hospital Motol, Prague, Czech Republic.
Funding
No grant is acknowledged in the PubMed record.
Abstract
PubMed holds no abstract for this paper.
Indexed as
High-Throughput Nucleotide SequencingHumansNeoplasm, ResidualPolymerase Chain ReactionPrecursor Cell Lymphoblastic Leukemia-LymphomaPredictive Value of TestsRecurrence
Identifiers
What OpenQuestion holds
Textmetadata
Read underepoch 390
Registered trials
None linked
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.